
## Hui-Chu Lang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8503744/publications.pdf Version: 2024-02-01



HUI-CHULANC

#	Article	IF	CITATIONS
1	Statins decrease the risk of decompensation in hepatitis B virus– and hepatitis C virus–related cirrhosis: A populationâ€based study. Hepatology, 2017, 66, 896-907.	7.3	89
2	Validation of EQ-5D in patients with cervical cancer in Taiwan. Supportive Care in Cancer, 2010, 18, 1279-1286.	2.2	46
3	Willingness to Pay for Lung Cancer Treatment. Value in Health, 2010, 13, 743-749.	0.3	42
4	Comparison of Clinical Outcomes in Patients Undergoing Coronary Intervention with Drug-Eluting Stents or Bare-Metal Stents: A Nationwide Population Study. Acta Cardiologica Sinica, 2017, 33, 10-19.	0.2	30
5	Impact of the case payment reimbursement method on the utilization and costs of laparoscopic cholecystectomy. Health Policy, 2004, 67, 195-206.	3.0	28
6	Risk of tuberculosis, serious infection and lymphoma with diseaseâ€modifying biologic drugs in rheumatoid arthritis patients in Taiwan. International Journal of Rheumatic Diseases, 2014, 17, 9-19.	1.9	28
7	The Lifetime Cost of Hepatocellular Carcinoma. Applied Health Economics and Health Policy, 2008, 6, 55-65.	2.1	23
8	The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan. Journal of Medical Economics, 2016, 19, 923-927.	2.1	23
9	Lifetime costs of the top five cancers in Taiwan. European Journal of Health Economics, 2012, 13, 347-353.	2.8	22
10	QUALITY OF LIFE, TREATMENTS, AND PATIENTS' WILLINGNESS TO PAY FOR A COMPLETE REMISSION OF CERVICAL CANCER IN TAIWAN. Health Economics (United Kingdom), 2012, 21, 1217-1233.	1.7	22
11	Risk of major depression in patients with chronic renal failure on different treatment modalities: A matchedâ€cohort and populationâ€based study in <scp>T</scp> aiwan. Hemodialysis International, 2016, 20, 98-105.	0.9	21
12	The Cost of Schizophrenia Treatment in Taiwan. Psychiatric Services, 2004, 55, 928-930.	2.0	18
13	Evaluating the Operational Efficiency and Quality of Tertiary Hospitals in Taiwan: The Application of the EBITDA Indicator to the DEA Method and TOBIT Regression. Healthcare (Switzerland), 2022, 10, 58.	2.0	15
14	Willingness to pay to sustain and expand National Health Insurance services in Taiwan. BMC Health Services Research, 2008, 8, 261.	2.2	13
15	The discrepancy in attention deficit hyperactivity disorder (ADHD) medications diffusion: 1994–2003—A global pharmaceutical data analysis. Health Policy, 2010, 97, 71-78.	3.0	13
16	Real-world cost-effectiveness of drug-eluting stents vs. bare-metal stents for coronary heart disease—A five-year follow-up study. Health Policy, 2019, 123, 229-234.	3.0	9
17	Outpatient drug expenditures and prescription policies for diseases with high cost to the National Health Insurance system in Taiwan. Journal of the Formosan Medical Association, 2004, 103, 280-5.	1.7	6
18	Evaluating the comparative efficiency of medical centers in Taiwan: a dynamic data envelopment analysis application. BMC Health Services Research, 2022, 22, 435.	2.2	6

Hui-Chu Lang

#	Article	IF	CITATIONS
19	Effects of hospital generic drug substitution on diabetes therapy. Patient Preference and Adherence, 2014, 8, 127.	1.8	5
20	The impact of introducing biologics to patients with rheumatoid arthritis in <scp>T</scp> aiwan: a populationâ€based trend study. International Journal of Rheumatic Diseases, 2016, 19, 1112-1118.	1.9	5
21	Risks of hepatocellular carcinoma and cirrhosis-associated complications in patients with rheumatoid arthritis: a 10-year population-based cohort study in Taiwan. Hepatology International, 2018, 12, 531-543.	4.2	5
22	Potentially preventable hospital readmissions after patients' first stroke in Taiwan. Scientific Reports, 2022, 12, 3743.	3.3	5
23	Association between continuity of care and long-term mortality in Taiwanese first-ever stroke survivors: An 8-year cohort study. PLoS ONE, 2019, 14, e0216495.	2.5	4
24	Cost-utility analysis of stereotactic body radiotherapy plus cetuximab in previously irradiated recurrent squamous cell carcinoma of the head and neck. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 489-495.	1.4	3
25	Cost–effectiveness of immune checkpoint inhibitors in the treatment of non-small-cell lung cancer as a second line in Taiwan. Future Oncology, 2022, , .	2.4	1